SCHEMBL3103070

SCHEMBL3103070

COc1cnc2c(c1)cc(C=O)n2Cc1ccc(Cl)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
USP2 O75604 4/20 0.40
HSD17B10 Q99714 4/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2C19 P33261 3/20 0.40
CASP1 P29466 3/20 0.40
CASP7 P55210 3/20 0.40
MAPK1 P28482 2/20 0.40
HIF1A Q16665 2/20 0.40
LMNA P02545 5/20 0.40
TP53 P04637 3/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
TSHR P16473 1/20 0.40
MDM4 O15151 1/20 0.39
MDM2 Q00987 1/20 0.39
CCR2 P41597 1/20 0.39
KDM4E B2RXH2 1/20 0.39
PDE1B Q01064 3/20 0.38
MAPT P10636 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095865 0.85 CCR2 (0.43) ALDH1A1CYP1A2CYP2C19MAPK1HIF1A
SCHEMBL3095854 0.85 CCR2 (0.43) ALDH1A1CYP1A2CYP2C19MAPK1HIF1A
SCHEMBL9959514 0.83 TP53 (0.44) ALDH1A1USP2HSD17B10CYP1A2CYP2C19
SCHEMBL12966284 0.82 P2RX3 (0.46) ALDH1A1USP2HSD17B10CYP1A2CYP2C19
SCHEMBL3083866 0.82 MEN1 (0.36) ALDH1A1USP2HSD17B10CYP1A2CYP2C19
SCHEMBL3088330 0.80 TP53 (0.46) ALDH1A1USP2HSD17B10CYP1A2CYP2C19
SCHEMBL30661270 0.79 DCTPP1 (0.42) ALDH1A1USP2CYP1A2MAPK1HIF1A
SCHEMBL29133960 0.79 DCTPP1 (0.42) ALDH1A1USP2CYP1A2MAPK1HIF1A
SCHEMBL3090980 0.77 LMNA (0.48) ALDH1A1CYP1A2CYP2C19MAPK1HIF1A
SCHEMBL3096637 0.77 MAPT (0.52) ALDH1A1USP2HSD17B10CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1933842-B1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS PANMIRA PHARMACEUTICALS LLC (US) 2012-10-03 EP disclosed
EP-1933842-B1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS PANMIRA PHARMACEUTICALS LLC (US) 2012-10-03 EP disclosed
US-7795274-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC. (US) 2010-09-14 US disclosed
US-7795274-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC. (US) 2010-09-14 US disclosed
US-7795274-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC. (US) 2010-09-14 US disclosed
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
US-7405302-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-7405302-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-7405302-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed
WO-2007047207-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 ALDH1A1 1358/4885USP2 2080/4885HSD17B10 572/4885
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 ALDH1A1 1358/4885USP2 2080/4885HSD17B10 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.